EFS de Versailles, centre de soins
Chesnay, Île-de-France Region, 78150, France
NCT Number: NCT03889834
The purpose of this study is to evaluate if differences between samples of subjects obtained before autologous blood transfusion or samples of non-transfused subjects and samples of subjects after autologous blood transfusion can be identified. Analyses performed will focus on the morphological and biochemical parameters of red blood cells and associated microparticles. The final goal would be to find markers of autologous blood transfusion, that could be used to identify such doping practice.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Chesnay, Île-de-France Region, 78150, France
Methodology and study design:
Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS (Etablissement Français du Sang) and INSERM (Institut National de la Santé et de la Recherche Médicale) partners, and leader of the Centre d'Investigation Clinique (CIC) Necker (Hospital Necker, Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium AP-HP (assistance Publique-Hôpitaux de Paris).
To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood packed red blood cells (after leuko deprivation and centrifugation) will be either stored at 4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 33 days later.
A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be separated in 3 groups:
To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be performed by EFS (Versailles, France). ABT as well as collection of samples will be performed at the CIC Necker (Paris, France). Blood samples will be collected before blood removal, the day of the ABT just before reinfusion and after 3 hours, 8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml BD Vacutainer EDTA tubes) will be taken at each time point:
1 will be dispatched to the French anti-doping laboratory (LADF) for haematological analysis (Orsay, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2 to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for proteomic analysis and Western-Blot.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 33 days
no transfusion
Time frame: Baseline (Day 1), until 2 days after autotransfusion
erythrocytes (/µL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
hemoglobin (g/dL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Hematocrit (%)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Mean corpuscular volume (fL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Reticulocyte by Sysmex analyzer
Time frame: Baseline (Day 1), until 2 days after autotransfusion
By amnis imaging flow cytometryProteins in Red blood cells (Wblot/ELISA/FACS)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Western blot /ELISA/ fluorescence-activated cell sorting of red blood cells
Time frame: Baseline (Day 1), until 2 days after autotransfusion
fluorescence-activated cell sorting
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Assay by LC-MS/MS in urine
Assistance Publique - Hôpitaux de Paris
Other
Modification of Biological Parameters After Autologous Blood Transfusion of a Small Volume of Packed Red Blood Cells (200 ml) in Healthy Volunteers
Acronym: AUTOT-SPORT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.